Developer docs
API playgroundTry for free, no card

Search company profiles

GenomOncology

Full company profile

uuid0002px3

Namestring
GenomOncology
Legal namestring
GenomOncology LLC
Company typeenum
Private
Founded yearint
2012
Descriptiontext

GenomOncology is a Cleveland, Ohio-based precision oncology software company founded in 2012 that provides an AI-enabled platform translating next-generation sequencing and clinical data into actionable decision support for oncology professionals. The company serves 50+ healthcare institutions across the United States, including molecular pathology labs, comprehensive cancer centers, diagnostic companies, and health systems. Its core products are organized under the Precision Oncology Platform (POP) umbrella and include GO Pathology Workbench (tertiary variant analysis and customizable clinical reporting), GO Molecular Tumor Board (multidisciplinary decision support with embedded trial recommendations), Clinical Trial Matching (automated patient-to-trial matching across 15,000+ active trials), the Precision Oncology API Suite (bidirectional HL7 integration without middleware), igniteIQ (NLP/OCR data enablement that extracts and normalizes unstructured pathology reports and clinical notes), GenomAnalytics, and BioMCP, an open-source Model Context Protocol for biomedical AI assistants released in 2025.

Underlying technology combines AI/NLP pipelines tuned for biomedical text, OCR with biomedical spell correction and image cleaning, ontology-linked normalization against standards such as ICD-O, HGNC, MONDO, HPO, and LOINC, and a curated content library spanning FDA indications, clinical trials, and integrated third-party evidence such as Genomenon Mastermind. The platform supports HIPAA-compliant cloud and on-premise deployment and integrates directly with EHR systems (notably a first-of-its-kind MEDITECH Expanse Genomics integration), sequencing platforms (PacBio HiFi long-read WGS, Pillar Biosciences panels), and laboratory information systems.

The business model is subscription-based enterprise SaaS delivered primarily through direct enterprise field sales led by a Chief Commercial Officer, with a 5-step sales process (discovery, demo, technical review, proposal, implementation). Distribution is augmented by channel and OEM-style integrations with diagnostic laboratories (Belay Diagnostics, Chronetyx Laboratories, OHSU Knight Diagnostics Lab) that embed the platform into high-volume NGS workflows, and by EHR and sequencing-platform partnerships that expand reach without resellers. Pricing is not publicly disclosed and is quote-based. The company completed a Series B funding round in 2023, is structured as an Ohio LLC, and reports a headcount band of 51-100.

Short descriptiontext

GenomOncology provides AI-enabled precision oncology software that transforms genomic and clinical data into actionable decision support for molecular pathologists, oncologists, bioinformaticians, and diagnostic laboratories across 50+ U.S. healthcare institutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCleveland, United States
HQ citystring
Cleveland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical decision support, precision oncology software, molecular pathology platform, clinical trial matching, genomic data enablement
Industry4 codes
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Software Publishers5132
  • Computer Systems Design and Related Services54151
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Computer Programming Services7371
Product category
Precision Oncology Clinical Decision Support Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Precision Oncology Platform Licensing
TypeSubscription Recurring
Description

Software platform licensing model providing access to GO Pathology Workbench, Clinical Trial Matching, and Data Enablement solutions. Subscription-based pricing with implementation and support services.

genomoncology.com
2Enterprise Software Solutions
TypeSubscription Recurring
Description

Comprehensive end-to-end software solutions for molecular pathology labs, clinical trial optimization, and data enablement delivered as integrated platform access.

genomoncology.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1GO Pathology Workbench
Description

Clinical genomic data analysis and reporting platform for molecular pathology labs.

genomoncology.com
+3 more records
Core offering1 text field

GenomOncology develops and licenses the Precision Oncology Platform (POP), an AI-enabled clinical decision support software suite for molecular pathology labs, oncologists, and researchers. Its core modules include GO Pathology Workbench for variant analysis and reporting, Clinical Trial Matching across 15,000+ trials, GO Molecular Tumor Board, and igniteIQ for data enablement via NLP/OCR. The platform integrates directly with EHR, LIS, and LIMS systems using HL7 and is offered as cloud or on-premise subscriptions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 3x increase in clinical trial enrollment at early adopter institutions
+4 more records
Product overview1 text field

GenomOncology offers the Precision Oncology Platform (POP), a unified platform architecture comprising multiple integrated solutions. The core offerings include GO Pathology Workbench for molecular pathology reporting and variant analysis, Clinical Trial Matching for automated patient-trial matching across 15,000+ trials, GO Molecular Tumor Board for multidisciplinary decision support, igniteIQ for data enablement and NLP/OCR extraction, GenomAnalytics for institutional analytics, and BioMCP for biomedical AI integration. The platform supports both cloud and on-premise deployment with direct HL7/EHR integration without middleware. The three main solution areas are Molecular Pathology Solutions (GO Pathology Workbench, GO Connect), Clinical Trial Optimization (Clinical Trial Matching, GO Molecular Tumor Board, Precision Oncology API Suite), and Data Enablement (igniteIQ, GenomAnalytics).

Product and service8 records
1GO Pathology Workbench
CategoryMolecular Pathology Software
2GO Connect
CategoryLaboratory Integration Software
3Clinical Trial Matching
CategoryClinical Trial Optimization Software
4GO Molecular Tumor Board
CategoryClinical Decision Support Software
5Precision Oncology API Suite
CategoryAPI / Integration Platform
6igniteIQ
CategoryData Enablement Software
7GenomAnalytics
CategoryAnalytics Software
8BioMCP
CategoryAI Integration / Open-Source Software
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-10
Description

Strategic partnership embedding WeTrials' AI-powered patient engagement platform directly within GO Genomic Reports. Enables clinicians to move from molecular reports with matched trial recommendations directly into WeTrials' patient-friendly trial enrollment interface. Initial focus on CNS cancer patients tested through Belay Diagnostics, with expansion planned to additional diagnostic partners and cancer types.

2OHSU Knight Diagnostics Lab
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-14
Description

Implementation of GO Clinical Trials Matching Solution integrating directly into KDL's diagnostic workflow. Automatically matches patients to open trials based on molecular profiles and clinical characteristics. Enables pathologists to generate customized matches within minutes rather than hours or days.

genomoncology.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-11
Description

Pathology Workbench platform integrated into Foundation's new genomic testing laboratory for glioblastoma. Operational within two weeks of contract signing. Supports comprehensive genomic panel testing, RNA fusion analysis, and whole genome sequencing methylation testing for MGMT.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2025-04-10
Description

Integrated end-to-end workflow combining PacBio HiFi whole-genome sequencing with GenomOncology Pathology Workbench for clinical labs. Supports configurable, reimbursement-aligned genomic reports across tumor types.

5Chronetyx Laboratories
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2025-03-31
Description

Pathology Workbench integration as tertiary analysis platform supporting Chronetyx Laboratories' FDA cleared Cyx Solid Tumor 505 test. Significantly reduces turnaround times by eliminating manual processes and automating complex genomic interpretations.

genomoncology.com
6Belay Diagnostics
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-03-25
Description

GO Pathology Workbench integrated into Belay Diagnostics' variant interpretation workflow for Summit liquid biopsy test. Supports thousands of samples per month for CNS cancer detection. Partnership reduces laboratory overhead and accelerates review, providing faster access to treatment recommendations.

genomoncology.com
7Pillar Biosciences
Strategic tierMajorTypeGTM or Marketing PartnerAnnounced on2025-02-13
Description

Co-marketing partnership integrating GenomOncology's clinical decision support platform with Pillar's research-use-only targeted NGS panels. Enables seamless workflow from NGS sequencer to clinical report with combined genomic data and decision support.

genomoncology.com
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2024-01-01
Description

Integration of Genomenon's Mastermind Data into GenomOncology's knowledgebase for enhanced germline variant classification. Content includes evidence supporting variant classifications, gene-disease relationships, and evidence automations aligned with ACMG guidelines and ClinGen standards.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-01-01
Description

Integration between MEDITECH Expanse Genomics solution and GenomOncology Precision Oncology Platform. Embeds comprehensive precision medicine information including treatment recommendations and clinical trials within Expanse EHR workflow. First-of-its-kind integration driving targeted cancer treatments.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Data enablement partnership using GenomOncology's igniteIQ solution within City of Hope's POSEIDON platform. NLP-based clinical data integration with expert-in-the-loop model for biomarker normalization and structure detection.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Flatiron Health (acquired by Roche) is a leading oncology-specific EHR and real-world data platform serving community oncology practices, academic centers, and life sciences companies. It directly overlaps with GenomOncology in clinical decision support, molecular profiling interpretation, and trial matching — but at much larger scale and with deeper pharma relationships.

2Tempus Labs
TypeBroad incumbent
Description

Tempus is an AI-enabled precision medicine platform offering NGS profiling, clinical trial matching, and decision support across oncology. Like GenomOncology, Tempus operates a molecular pathology interpretation layer and clinical trial matching engine, but with a much broader biopharma-services business and larger capital base.

TypeBroad incumbent
Description

Foundation Medicine (acquired by Roche) provides comprehensive genomic profiling and a molecular knowledge base widely used by oncologists. It competes with GenomOncology's Pathology Workbench on variant interpretation, but typically upstream of tertiary analysis as the test provider rather than the software platform layer.

TypeDirect peer
Description

SOPHiA Genetics offers a genomics interpretation platform used by hospitals and labs worldwide for variant calling and clinical reporting across hereditary oncology, solid tumors, and rare disease. It is a direct competitor to GenomOncology's GO Pathology Workbench and igniteIQ, with a comparable SaaS-to-labs model.

TypeDirect peer
Description

Velsera provides a clinical genomics cloud informatics platform including tertiary analysis, NGS workflows, and decision support for molecular pathology labs. It is a direct competitor to GenomOncology's Precision Oncology Platform, particularly with hospital and academic medical center labs.

TypeDirect peer
Description

Pierian was a clinical genomics interpretation and reporting platform for molecular pathology labs before its acquisition; GenomOncology's CCO Garreth Hippe previously led commercial growth at Pierian. It is a near-identical competitive reference point for GO Pathology Workbench.

TypeDirect peer
Description

Molecular Health offers a precision medicine decision support platform — including MH Guide for clinical interpretation of genomic variants and Dataome for biomedical knowledge — competing directly with GenomOncology's Pathology Workbench and Clinical Trial Matching offerings.

TypeDirect peer
Description

Inspirata provides a digital pathology workflow and oncology case-management platform used by pathology labs and cancer centers. It overlaps with GenomOncology in molecular pathology workflow automation and oncology decision support for labs and tumor boards.

TypeEmerging player
Description

2bPrecise (now part of Tempus) embeds precision medicine and pharmacogenomics decision support directly into the EHR. It is a comparable peer to GenomOncology's MEDITECH/Expanse integration approach and a relevant competitor for in-EHR oncology CDS.

TypeBroad incumbent
Description

Philips offers an enterprise digital pathology suite (IntelliSite) plus broader oncology informatics used by hospitals and pathology networks. It competes more broadly with GenomOncology in pathology workflow and oncology decision support, but as part of a much wider imaging and clinical informatics portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GenomOncology

Precision Oncology Clinical Decision Support Softwaregenomoncology.com

GenomOncology provides AI-enabled precision oncology software that transforms genomic and clinical data into actionable decision support for molecular pathologists, oncologists, bioinformaticians, and diagnostic laboratories across 50+ U.S. healthcare institutions.

What GenomOncology does

GenomOncology is a Cleveland, Ohio-based precision oncology software company founded in 2012 that provides an AI-enabled platform translating next-generation sequencing and clinical data into actionable decision support for oncology professionals. The company serves 50+ healthcare institutions across the United States, including molecular pathology labs, comprehensive cancer centers, diagnostic companies, and health systems. Its core products are organized under the Precision Oncology Platform (POP) umbrella and include GO Pathology Workbench (tertiary variant analysis and customizable clinical reporting), GO Molecular Tumor Board (multidisciplinary decision support with embedded trial recommendations), Clinical Trial Matching (automated patient-to-trial matching across 15,000+ active trials), the Precision Oncology API Suite (bidirectional HL7 integration without middleware), igniteIQ (NLP/OCR data enablement that extracts and normalizes unstructured pathology reports and clinical notes), GenomAnalytics, and BioMCP, an open-source Model Context Protocol for biomedical AI assistants released in 2025.

Underlying technology combines AI/NLP pipelines tuned for biomedical text, OCR with biomedical spell correction and image cleaning, ontology-linked normalization against standards such as ICD-O, HGNC, MONDO, HPO, and LOINC, and a curated content library spanning FDA indications, clinical trials, and integrated third-party evidence such as Genomenon Mastermind. The platform supports HIPAA-compliant cloud and on-premise deployment and integrates directly with EHR systems (notably a first-of-its-kind MEDITECH Expanse Genomics integration), sequencing platforms (PacBio HiFi long-read WGS, Pillar Biosciences panels), and laboratory information systems.

The business model is subscription-based enterprise SaaS delivered primarily through direct enterprise field sales led by a Chief Commercial Officer, with a 5-step sales process (discovery, demo, technical review, proposal, implementation). Distribution is augmented by channel and OEM-style integrations with diagnostic laboratories (Belay Diagnostics, Chronetyx Laboratories, OHSU Knight Diagnostics Lab) that embed the platform into high-volume NGS workflows, and by EHR and sequencing-platform partnerships that expand reach without resellers. Pricing is not publicly disclosed and is quote-based. The company completed a Series B funding round in 2023, is structured as an Ohio LLC, and reports a headcount band of 51-100.

GenomOncology firmographics

Firmographics
Name
GenomOncology
Legal name
GenomOncology LLC
Website
https://genomoncology.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
GenomOncology provides AI-enabled precision oncology software that transforms genomic and clinical data into actionable decision support for molecular pathologists, oncologists, bioinformaticians, and diagnostic laboratories across 50+ U.S. healthcare institutions.
Ownership category
akta.pro rank

GenomOncology industry classification

Industry
Product category
Precision Oncology Clinical Decision Support Software
NAICS
Software Publishers (5132), Computer Systems Design and Related Services (54151)
SIC
Services-Prepackaged Software (7372), Services-Computer Programming Services (7371)
akta.pro industry
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Clinical decision support
  • Precision oncology software
  • Molecular pathology platform
  • Clinical trial matching
  • Genomic data enablement

Where GenomOncology is headquartered

Location

Headquarters

HQ city
Cleveland
HQ country
United States
HQ region
North America

Offices1 record

Markets served

GenomOncology business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Precision Oncology Platform Licensing: Software platform licensing model providing access to GO Pathology Workbench, Clinical Trial Matching, and Data Enablement solutions. Subscription-based pricing with implementation and support services.
  2. Enterprise Software Solutions: Comprehensive end-to-end software solutions for molecular pathology labs, clinical trial optimization, and data enablement delivered as integrated platform access.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

GenomOncology product offering

Product offering

Core offering

GenomOncology develops and licenses the Precision Oncology Platform (POP), an AI-enabled clinical decision support software suite for molecular pathology labs, oncologists, and researchers. Its core modules include GO Pathology Workbench for variant analysis and reporting, Clinical Trial Matching across 15,000+ trials, GO Molecular Tumor Board, and igniteIQ for data enablement via NLP/OCR. The platform integrates directly with EHR, LIS, and LIMS systems using HL7 and is offered as cloud or on-premise subscriptions.

Product overview

GenomOncology offers the Precision Oncology Platform (POP), a unified platform architecture comprising multiple integrated solutions. The core offerings include GO Pathology Workbench for molecular pathology reporting and variant analysis, Clinical Trial Matching for automated patient-trial matching across 15,000+ trials, GO Molecular Tumor Board for multidisciplinary decision support, igniteIQ for data enablement and NLP/OCR extraction, GenomAnalytics for institutional analytics, and BioMCP for biomedical AI integration. The platform supports both cloud and on-premise deployment with direct HL7/EHR integration without middleware. The three main solution areas are Molecular Pathology Solutions (GO Pathology Workbench, GO Connect), Clinical Trial Optimization (Clinical Trial Matching, GO Molecular Tumor Board, Precision Oncology API Suite), and Data Enablement (igniteIQ, GenomAnalytics).

Differentiator

Problem solved

Functional benefit

Brands

  • GO Pathology Workbench: Clinical genomic data analysis and reporting platform for molecular pathology labs.
  • BioMCP
  • igniteIQ
  • Precision Oncology Platform (POP)

Products and services

  • GO Pathology Workbench
  • GO Connect
  • Clinical Trial Matching
  • GO Molecular Tumor Board
  • Precision Oncology API Suite
  • igniteIQ
  • GenomAnalytics
  • BioMCP

Quantifiable outcome

  • 3x increase in clinical trial enrollment at early adopter institutions
  • +4 more outcomes

Companies that use GenomOncology

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles3 records

GenomOncology technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability9 records

Feature6 records

GenomOncology partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, strategic and major.

  • WeTrialscoreStrategic or Co-development Partner · 10 March 2026Strategic partnership embedding WeTrials' AI-powered patient engagement platform directly within GO Genomic Reports. Enables clinicians to move from molecular reports with matched trial recommendations directly into WeTrials' patient-friendly trial enrollment interface. Initial focus on CNS cancer patients tested through Belay Diagnostics, with expansion planned to additional diagnostic partners and cancer types.
  • OHSU Knight Diagnostics LabcoreTechnology or Integration · 14 January 2026Implementation of GO Clinical Trials Matching Solution integrating directly into KDL's diagnostic workflow. Automatically matches patients to open trials based on molecular profiles and clinical characteristics. Enables pathologists to generate customized matches within minutes rather than hours or days.
  • Glioblastoma FoundationcoreStrategic or Co-development Partner · 11 November 2025Pathology Workbench platform integrated into Foundation's new genomic testing laboratory for glioblastoma. Operational within two weeks of contract signing. Supports comprehensive genomic panel testing, RNA fusion analysis, and whole genome sequencing methylation testing for MGMT.
  • PacBiostrategicTechnology or Integration · 10 April 2025Integrated end-to-end workflow combining PacBio HiFi whole-genome sequencing with GenomOncology Pathology Workbench for clinical labs. Supports configurable, reimbursement-aligned genomic reports across tumor types.
  • Chronetyx LaboratoriesmajorTechnology or Integration · 31 March 2025Pathology Workbench integration as tertiary analysis platform supporting Chronetyx Laboratories' FDA cleared Cyx Solid Tumor 505 test. Significantly reduces turnaround times by eliminating manual processes and automating complex genomic interpretations.
  • Belay DiagnosticscoreTechnology or Integration · 25 March 2025GO Pathology Workbench integrated into Belay Diagnostics' variant interpretation workflow for Summit liquid biopsy test. Supports thousands of samples per month for CNS cancer detection. Partnership reduces laboratory overhead and accelerates review, providing faster access to treatment recommendations.
  • Pillar BiosciencesmajorGTM or Marketing Partner · 13 February 2025Co-marketing partnership integrating GenomOncology's clinical decision support platform with Pillar's research-use-only targeted NGS panels. Enables seamless workflow from NGS sequencer to clinical report with combined genomic data and decision support.
  • GenomenonmajorTechnology or Integration · 1 January 2024Integration of Genomenon's Mastermind Data into GenomOncology's knowledgebase for enhanced germline variant classification. Content includes evidence supporting variant classifications, gene-disease relationships, and evidence automations aligned with ACMG guidelines and ClinGen standards.
  • MEDITECHcoreTechnology or Integration · 1 January 2024Integration between MEDITECH Expanse Genomics solution and GenomOncology Precision Oncology Platform. Embeds comprehensive precision medicine information including treatment recommendations and clinical trials within Expanse EHR workflow. First-of-its-kind integration driving targeted cancer treatments.
  • City of HopemajorStrategic or Co-development Partner · 1 January 2024Data enablement partnership using GenomOncology's igniteIQ solution within City of Hope's POSEIDON platform. NLP-based clinical data integration with expert-in-the-loop model for biomarker normalization and structure detection.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

GenomOncology competitors and assessment

Company assessment

Broad incumbents

  • Flatiron Health: Flatiron Health (acquired by Roche) is a leading oncology-specific EHR and real-world data platform serving community oncology practices, academic centers, and life sciences companies. It directly overlaps with GenomOncology in clinical decision support, molecular profiling interpretation, and trial matching — but at much larger scale and with deeper pharma relationships.
  • Tempus Labs: Tempus is an AI-enabled precision medicine platform offering NGS profiling, clinical trial matching, and decision support across oncology. Like GenomOncology, Tempus operates a molecular pathology interpretation layer and clinical trial matching engine, but with a much broader biopharma-services business and larger capital base.
  • Foundation Medicine: Foundation Medicine (acquired by Roche) provides comprehensive genomic profiling and a molecular knowledge base widely used by oncologists. It competes with GenomOncology's Pathology Workbench on variant interpretation, but typically upstream of tertiary analysis as the test provider rather than the software platform layer.
  • Philips Digital Pathology: Philips offers an enterprise digital pathology suite (IntelliSite) plus broader oncology informatics used by hospitals and pathology networks. It competes more broadly with GenomOncology in pathology workflow and oncology decision support, but as part of a much wider imaging and clinical informatics portfolio.

Direct peers

  • SOPHiA Genetics: SOPHiA Genetics offers a genomics interpretation platform used by hospitals and labs worldwide for variant calling and clinical reporting across hereditary oncology, solid tumors, and rare disease. It is a direct competitor to GenomOncology's GO Pathology Workbench and igniteIQ, with a comparable SaaS-to-labs model.
  • Velsera (formerly Seven Bridges): Velsera provides a clinical genomics cloud informatics platform including tertiary analysis, NGS workflows, and decision support for molecular pathology labs. It is a direct competitor to GenomOncology's Precision Oncology Platform, particularly with hospital and academic medical center labs.
  • Pierian (acquired by Illumina/Agilent): Pierian was a clinical genomics interpretation and reporting platform for molecular pathology labs before its acquisition; GenomOncology's CCO Garreth Hippe previously led commercial growth at Pierian. It is a near-identical competitive reference point for GO Pathology Workbench.
  • Molecular Health: Molecular Health offers a precision medicine decision support platform — including MH Guide for clinical interpretation of genomic variants and Dataome for biomedical knowledge — competing directly with GenomOncology's Pathology Workbench and Clinical Trial Matching offerings.
  • Inspirata: Inspirata provides a digital pathology workflow and oncology case-management platform used by pathology labs and cancer centers. It overlaps with GenomOncology in molecular pathology workflow automation and oncology decision support for labs and tumor boards.

Emerging players

  • 2bPrecise: 2bPrecise (now part of Tempus) embeds precision medicine and pharmacogenomics decision support directly into the EHR. It is a comparable peer to GenomOncology's MEDITECH/Expanse integration approach and a relevant competitor for in-EHR oncology CDS.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

GenomOncology social profiles

Digital presence

GenomOncology compliance and trust

Trust signal

Compliance1 record

GenomOncology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GenomOncology leadership team

Management profile

Number of profiles

Profiles15 records

GenomOncology funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GenomOncology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GenomOncology

What does GenomOncology do?

GenomOncology develops and licenses the Precision Oncology Platform (POP), an AI-enabled clinical decision support software suite for molecular pathology labs, oncologists, and researchers. Its core modules include GO Pathology Workbench for variant analysis and reporting, Clinical Trial Matching across 15,000+ trials, GO Molecular Tumor Board, and igniteIQ for data enablement via NLP/OCR. The platform integrates directly with EHR, LIS, and LIMS systems using HL7 and is offered as cloud or on-premise subscriptions.

Is GenomOncology a public or private company?

GenomOncology is a private company. It is classified as venture growth investor backed and is currently operating.

When was GenomOncology founded?

GenomOncology was founded in 2012. It employs 11 to 50 people.

Where is GenomOncology based?

GenomOncology is headquartered in Cleveland, United States, in the North America region.

How does GenomOncology make money?

Two revenue lines are on record. Precision Oncology Platform Licensing is the primary driver. The others are enterprise Software Solutions.

Who are GenomOncology's main competitors?

Broad incumbents on record are Flatiron Health, Tempus Labs, Foundation Medicine and Philips Digital Pathology. Direct peers are SOPHiA Genetics, Velsera (formerly Seven Bridges), Pierian (acquired by Illumina/Agilent), Molecular Health and Inspirata. 2bPrecise is listed as an emerging player.

Does GenomOncology have an API?

Yes. GenomOncology offers API capabilities including the Precision Oncology API Suite which enables clinical trial matching, therapy recommendations, and genomic data exchange. The platform supports bidirectional HL7 integration with no middleware required, allowing direct EHR integration for automated order acceptance and discrete genomic findings delivery. The platform also offers BioMCP, an open-source Model Context Protocol implementation for biomedical AI assistants and agents that supports advanced searching and full-text retrieval from clinical trials, genetic data, and published medical research. Developer documentation is at biomcp.org.

What industry is GenomOncology in?

GenomOncology's product category is Precision Oncology Clinical Decision Support Software. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialGenomoncology Integrates ARUP Laboratories' Jalapheno Phenotype-Matching Tool Into GO Pathology Workbench Under Multiyear Exclusive AgreementGenomOncology and ARUP Laboratories announced a multiyear exclusive agreement to integrate Jalapheno, a phenotype-driven gene prioritization tool, into GO Pathology Workbench. The tool generates HPO-based phenotype-matching scores that feed into variant prioritization, supporting germline sequencing for rare disease. Optional AI-driven workflows for variant classification and interpretation are also introduced.The future of tradingGenomOncology Integrates ARUP Laboratories’ Jalapheno Phenotype-Matching Tool Into GO Pathology Workbench Under Multiyear Exclusive AgreementGenomOncology and ARUP Laboratories announced a multiyear exclusive agreement integrating Jalapheno, a phenotype-driven gene prioritization tool, into GO Pathology Workbench. The tool generates phenotype-matching scores from clinical features and feeds into variant prioritization, supporting germline sequencing for rare disease. Specific terms were not disclosed.FinancialContent Business PageGenomOncology Integrates ARUP Laboratories’ Jalapheno Phenotype-Matching Tool Into GO Pathology Workbench Under Multiyear Exclusive AgreementGenomOncology and ARUP Laboratories announced a multiyear exclusive agreement to integrate Jalapheno, a phenotype-driven gene prioritization tool, into GO Pathology Workbench. The tool generates gene-level phenotype-matching scores from clinical features and is available to all GenomOncology customers. Specific terms of the agreement were not disclosed.Clinical Lab ProductsGenomOncology, PacBio Unveil Integrated Oncology Sequencing WorkflowGenomOncology and PacBio have unveiled an integrated end-to-end workflow for somatic whole-genome sequencing in oncology, combining PacBio's HiFi WGS analysis pipeline with GenomOncology's Pathology Workbench platform. This solution aims to standardize clinical reporting by translating long-read sequencing data into structured, clinician-ready reports for pathology laboratories. The system supports modular reporting for specific tumor types and can be deployed on-premises or via public cloud platforms.openPR.comGlioma Market to Expand Rapidly with Advancing Pipeline and Increasing Treatment Adoption by 2036 - DelveInsightDelveInsight Business Research released a market forecast report projecting the global glioma market to exceed USD 1 billion in 2025 with a 15% CAGR through 2036, driven by rising incidence and new therapeutic approvals. The United States holds the dominant market share, while key developments include FDA Breakthrough Therapy Designation for FORE Biotherapeutics' plixorafenib and strategic collaborations involving GenomOncology and Diakonos Oncology.The Manila TimesGenomOncology Announces Integrated End-to-End Workflow Using PacBio’s Long-Read Whole-Genome Sequencing Technology in OncologyGenomOncology announced an integrated end-to-end workflow combining PacBio’s HiFi long-read whole-genome sequencing technology with its Pathology Workbench software for oncology diagnostics. This solution addresses the operational challenge of translating complex sequencing data into standardized, clinician-ready reports by automating secondary and tertiary analysis steps. The platform allows clinical laboratories to generate customizable genomic reports aligned with specific tumor types and reimbursement requirements.GlobeNewswireGenomOncology Announces Integrated End-to-End Workflow Using PacBio’s Long-Read Whole-Genome Sequencing Technology in OncologyGenomOncology announced an end-to-end workflow combining PacBio HiFi WGS secondary analysis with its Pathology Workbench platform for oncology reporting. The modular system enables labs to generate clinician-ready reports with histology-specific sub-panels, supporting flexible deployment on-premises or in the cloud.PR NewswireGenomOncology Announces Strategic Partnership with WeTrials to Accelerate Clinical Trial Enrollment for CNS Cancer PatientsGenomOncology announced a strategic partnership with WeTrials to help CNS cancer patients access and enroll in clinical trials faster by embedding a direct link to WeTrials' platform within GenomOncology's GO Genomic Reports. The collaboration expands on GenomOncology's existing partnership with Belay Diagnostics, whose Summit™ 2.0 liquid biopsy test workflow will serve as the foundation for the integrated pathway from molecular diagnosis to trial enrollment. The initial phase will focus on CNS cancer patients tested through Belay Diagnostics, with plans to expand to additional diagnostic partners and cancer types over time.NewswiseGenomOncology Partners with OHSU Knight Diagnostics Lab to Accelerate Patient Access to Precision Oncology Clinical TrialsGenomOncology announced a strategic partnership with Oregon Health & Science University's Knight Diagnostics Lab to implement GO's Clinical Trials Matching Solution for cancer patients. The integration will automatically match patients to precision oncology trials based on their molecular profiles and clinical characteristics, embedding the matching process directly into KDL's diagnostic workflow. This automation enables pathologists to identify and validate relevant trial matches within minutes rather than hours or days, addressing a longstanding bottleneck in patient access to clinical trials.PR NewswireGenomOncology Partners with OHSU Knight Diagnostics Lab to Accelerate Patient Access to Precision Oncology Clinical TrialsGenomOncology announced a strategic partnership with Oregon Health & Science University's Knight Diagnostics Lab on January 14, 2026, to integrate its Clinical Trials Matching Solution into KDL's diagnostic workflow for improved cancer patient access to precision oncology trials. The system automatically matches patients to open trials based on their molecular profiles and clinical characteristics, enabling pathologists to generate customized, rapid matches within minutes rather than hours or days. The partnership addresses a bottleneck in precision oncology by automating trial identification and embedding it directly into the clinical decision support process.